Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers

Inclusion Criteria: * Healthy female volunteers between 18 and 30 years * With skin type I or skin type II * Body Mass Index \> 25 * Non-smokers * Volunteers who have given their written informed consent according to Good Clinical Practice (GCP) and local regulations Exclusion Criteria: * Any serious disorder that may interfere with her participation to the trial and evaluation of the safety of the test drug (e.g. liver and/or renal disease, hypervitaminosis A, psychic disorder, etc.), and/or treatment with chronic medication * Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug that may influence the trial symptomatology and may interfere with evaluation of the safety of the test drug (e.g. vitamins and minerals supplementation) * Relevant allergy or known hypersensitivity to the investigational drug or its excipients * High performance sports people * Alcohol and drug abuse according to Diagnostic and Statistics Manual (DSM-IV) * Female volunteers in child-bearing age not using adequate means of birth control (contraceptive pills, intrauterine device (IUDs), sterilization) * Pregnancy and/or lactation * Known abnormal values of the lab tests (if detected after enrolment, subjects will continue the treatment provided there are no medical objections) * Abnormal values of Aspartate Transferase (SGOT/ASAT), Alanine Transferase (SGPT/ALAT)-, Gamma-glutamyl transpeptidase, Low density Lipoproteins/Triglycerides (LDL/TGL) levels in blood * Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial * Specific dietary requirements that do not allow the volunteers to meet the dietary guidelines set out for this study